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Abstract
Introduction RP105 is a Toll-like receptor homolog expressed
on B cells, dendritic cells (DCs), and macrophages. We
investigated the role of RP105 in the development of collagen-
induced arthritis (CIA).
Methods CIA was induced in RP105-deficient DBA/1 mice and
the incidence and arthritis index were analyzed. The cytokine
production by spleen cells was determined. The functions of the
DCs and regulatory T cells (Tregs) from RP105-deficient or
control mice were determined by adding these cells to the lymph
node cell culture. Arthritis was also induced by incomplete
Freund's adjuvant (IFA) plus collagen or by injecting anti-
collagen antibody and lipopolysaccharide.
Results RP105-deficient mice showed accelerated onset of
arthritis and increased severity. Interferon-gamma (IFN-γ) and
tumor necrosis factor-alpha production by spleen cells from
RP105-deficient mice was increased in comparison with that
from wild-type mice. The DCs from RP105-deficient mice
induced more IFN-γ production, whereas Tregs from those mice
showed less inhibitory effect against IFN-γ production. RP105-
deficient mice also showed more severe arthritis induced by
collagen with IFA.
Conclusions These results indicate that RP105 regulates the
antigen-presenting cell function and Treg development, which
induced the attenuation of the cell-mediated immune responses
and, as a result, suppressed the development of CIA.
Introduction
The Toll-like receptor (TLR) family is composed of pattern rec-
ognition receptors that recognize the pathogen-associated
molecular patterns of microorganisms and trigger an innate
immune response [1]. The TLRs are expressed mainly on mac-
rophages and dendritic cells (DCs) and activate these cells
after binding to their ligands. The activation of TLRs has been
shown to induce proinflammatory cytokines, such as tumor
necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), and also
to cause the upregulation of costimulatory molecules which
activates the adaptive immune system [2,3]. Whereas the
TLRs play a key role for host defense, they also play important
roles in inflammatory diseases [4]. Rheumatoid arthritis (RA) is
a chronic autoimmune and inflammatory disease characterized
by synovial inflammation and destruction of cartilage and
bone. Recently, TLRs have been shown to play an important
role in arthritis both in humans and in experimental animal mod-
els. In RA, it has been shown that TLR2, TLR3, TLR4, and
TLR7 are upregulated in the synovium and synovial macro-
phages [5-9]. Some of these TLRs are upregulated by proin-
flammatory cytokines and, in turn, have a costimulatory
function [7,8]. The endogenous ligands of TLRs, such as heat
shock proteins [10-12], hyaluronan [13,14], or degradation
product of fibrinogen [15], are expressed in joints, and it is
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considered that they can activate DCs or macrophages via the
TLR, thus leading to the progression of arthritis in joints
[16,17].
In experimental animal models, the critical roles of the TLRs
and their adaptor molecule myeloid differentiation factor 88
(MyD88) in the development of arthritis have been demon-
strated in various models [18-22]. The data that the injection
of TLR3 and TLR9 ligands into the joints induced arthritis
[23,24] and that TLR9 ligand CpG immunization induces
arthritis in rats [25] further support an arthritogenic role of
TLRs. On the contrary, systemic TLR3 activation has been
shown to suppress antibody-induced and TCR-transgenic
mouse serum-induced arthritis [26], thus suggesting the dif-
ferent effect in arthritis between the local and systemic activa-
tion of TLRs.
RP105, expressed on B cells, macrophages, and DCs, is a
TLR homolog that lacks a conserved intracellular signaling
domain (Toll-IL-1 receptor domain) and forms a complex with
soluble protein MD-1 [27-29]. It has been shown that RP105
can provide proliferation and activation signals in B cells [28]
and that B cells from RP105-deficient mice were hyporespon-
sive to TLR4 and TLR2 stimulation [30,31]. We have been
working on RP105 on B cells in patients with autoimmune dis-
eases, including systemic lupus erythematosus. We previously
reported that B cells lacking RP105 expand in the peripheral
blood of patients with systemic lupus erythematosus [32] and
that these cells can produce anti-double-stranded DNA anti-
body [33]. On the other hand, Divanovic and colleagues [34]
showed that RP105 directly interacts with TLR4 and nega-
tively regulates TLR4 signaling by experiments using transfect-
ant cells and RP105-deficient mice-derived DCs.
In the present study, we investigated the role of RP105 in the
development of collagen-induced arthritis (CIA) using RP105-
deficient mice. CIA is an autoimmune inflammatory disease of
the joints which is induced by immunization with type II colla-
gen (CII). Our data show that RP105-deficient mice exhibit an
accelerated onset of more severe arthritis, with an increased
cytokine production of T cells and attenuated development of
regulatory T cells (Tregs). These results suggest that RP105
plays a regulatory role in cell-mediated immunity and the devel-
opment of CIA.
Materials and methods
Mice and experimental conditions
RP105-deficient mice [30] were backcrossed into the DBA/1
background for six generations and genotyped by polymerase
chain reaction using ear biopsy-derived DNA. In all experi-
ments, only RP105-/-, RP105+/-, and RP105+/+  littermates
were used. All mice were 12 to 16 weeks of age at the time of
immunization. The animals were maintained at the Saga Medi-
cal School animal facility. The care of the animals was in
accordance with the guidelines for animal experimentation of
the Saga Medical School. All animal experiments were
approved by the local ethical committee (University of Saga,
numbers 07-015-4 and 07-015-5).
Induction of collagen-induced arthritis
Mice were immunized intradermally at the base of the tail with
150 μg of bovine CII (Cosmo Bio Co. Ltd., Tokyo, Japan) emul-
sified with an equal volume of complete Freund's adjuvant
(CFA) containing 200 μg of H37RA Mycobacterium tubercu-
losis (Difco Laboratories Inc., now part of Becton Dickinson
and Company, Franklin Lakes, NJ, USA) on day 0. Mice were
boosted by an intradermal injection of 150 μg of bovine CII in
incomplete Freund's adjuvant (IFA) (Difco Laboratories Inc) on
day 21. Arthritis development was monitored by physical
examination three times per week and the inflammation in each
of the four paws was graded from 0 to 3, as described previ-
ously [35]. The four scores were added, with the maximum
score per mouse being 12. The arthritis index was calculated
by dividing the total score of the experimental mice by the
number of total mice or arthritic mice. In the additional experi-
ment, CIA was induced without CFA; the mice were immu-
nized with 200 μg of bovine CII emulsified with IFA on days 0
and 21.
Histology
The ankle joints of the mice were excised 5 weeks after immu-
nization and fixed in 10% buffered formalin, decalcified in 10%
EDTA (ethylenediaminetetraacetic acid), embedded in paraf-
fin, sectioned, and stained with hematoxylin and eosin. The
intensity of synovial hyperplasia, cellular infiltration, and pan-
nus formation was examined and arthritis was graded in a
blinded fashion on a scale of 0 to 4, as described previously
[36].
Measurement of the serum anti-CII antibody levels
The levels of serum antibodies to CII were measured by
enzyme-linked immunosorbent assay (ELISA) as previously
described [37]. Briefly, serial dilutions of serum samples were
added to the microtiter plates (Maxisorp; Nunc, Roskilde, Den-
mark), coated with native bovine CII at 10 μg/mL, and incu-
bated for 1 hour at 37°C. After washing, peroxidase-
conjugated goat anti-mouse IgG1 or IgG2a (SouthernBiotech,
Birmingham, AL, USA) was added and incubated for 1 hour at
37°C. Antibody binding was visualized using orthophenylene-
diamine (Sigma-Aldrich, St. Louis, MO, USA). A standard
serum composed of a mixture of sera from the arthritic mice
was added to each plate in serial dilutions and a standard
curve was constructed. The standard serum was defined as
100 U and antibody titers of serum samples were calculated
from the standard curve.
Measurement of cytokine production by spleen cells
Interferon-gamma (IFN-γ), TNF-α, and IL-2 and IL-4 production
was examined on day 28 in the spleen cells. The cells were
resuspended in Dulbecco's modified Eagle's medium (DMEM)Available online http://arthritis-research.com/content/10/5/R121
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with 2% autologous mouse serum, seeded at 6 × 106 per
wells in 24-well plates (Nunc), and stimulated with denatured
CII (dCII) or Con A (Sigma-Aldrich) for 48 hours. The
cytokines produced in the culture supernatant were measured
by the cytometric beads assay system (BD Biosciences, San
Jose, CA, USA) using FACSCalibur, except for the measure-
ment of IL-17, which was done by ELISA (R&D Systems, Min-
neapolis, MN, USA).
Preparation and functional analysis of splenic dendritic 
cells
The splenic DCs were purified by magnetic cell sorting using
CD11c microbeads (Miltenyi Biotec, Auburn, CA, USA) in
accordance with the manufacturer's instructions. Briefly, the
spleens from two or three mice immunized with CII 8 days
before were digested with collagenase D (Roche Diagnostics,
Penzberg, Germany). The spleen cells were incubated with
anti-CD16/32 antibody for blocking, labeled with CD11c
magnetic-activated cell sorting beads, and applied to mag-
netic column. After washing the column, the CD11c+ DCs
were obtained by flushing them out using a plunger. The
resultant cell purity was greater than 92% by flow cytometry.
The conventional DCs (cDCs) and plasmacytoid DCs (pDCs)
were determined by staining with anti-CD11c plus anti-B220
and anti-PDCA-1 plus anti-B220 (Miltenyi Biotec). For func-
tional analysis, the splenic DCs (50 or 12.5 × 104 cells) from
RP105+/+ or RP105-/- mice were mixed with pooled adherent
cell-removed lymph node cells (LNCs) (2.5 × 106 cells) from
RP105+/- mice, which were immunized with CII 8 days before.
The cells were resuspended in DMEM with 2% mouse serum
and stimulated with dCII for 3 days. The IFN-γ produced in the
culture supernatant was measured using ELISA kits (Bio-
source International, Camarillo, CA, USA).
Measurement of cytokine production by splenic 
dendritic cells
The splenic DCs from RP105+/+ and RP105-/- mice separated
as described were resuspended at 4 × 105 per well in 96-well
microtiter plates and stimulated with various concentrations of
lipopolysaccharide (LPS) (OB111; Sigma-Aldrich) for 24
hours. The cytokines produced in the culture supernatant were
measured by the cytometric beads assay system (BD Bio-
sciences) using FACSCalibur. The lower detection limit of
cytokines was 3.0 pg/mL in these experiments.
Preparation and functional analysis of regulatory T cells
The Tregs were purified from the spleens by magnetic cell
sorting using the CD4+CD25+ regulatory T-cell isolation kit
(Miltenyi Biotec) in accordance with the manufacturer's
instructions. Briefly, the spleens from three mice, immunized
with CII 4 weeks before, were digested with collagenase D
(Roche Diagnostics). The spleen cells were incubated with a
biotin-labeled antibody cocktail and further incubated with
anti-biotin microbeads and phycoerythrin-labeled anti-CD25
antibody. After washing, the cells were applied to the LD (lym-
phocyte depletion) column, and the T cells that passed
through the column were collected. Thereafter, the T cells
were incubated with anti-phycoerythrin microbeads, washed,
and applied to the LS (lymphocyte separation) column. After
washing the column, the CD4+CD25+ T cells were obtained
by flushing them out with a plunger. The resultant cell purity
was greater than 90% by flow cytometry, and the contaminat-
ing cells were mainly non-T non-B cells. Foxp3 staining was
performed to compare the purity and its expression in recov-
ered cells as well as whole spleen cells using fluorescein iso-
thiocyanate-conjugated anti-Foxp3 antibody (eBioscience,
San Diego, CA, USA). More than 95% of the recovered
CD4+CD25+ T cells were positive for Foxp3, which was not
different between cells from RP105+/+ or RP105-/- mice. For a
functional analysis, Tregs (1.0 × 105 cells) from RP105+/+ or
RP105-/- mice were added to the pooled LNCs (1.0 × 106
cells) from RP105+/- mice, which were immunized with CII 8
days before, resuspended in DMEM with 2% mouse sera, and
stimulated with dCII or anti-CD3 antibody (BD Biosciences)
for 3 days. The IFN-γ produced in the culture supernatant was
measured using ELISA kits (Biosource International).
Induction of anti-CII antibody-induced arthritis
Anti-CII antibody-induced arthritis was induced using a kit
(Chondrex Inc., Redmond, WA, USA). RP105+/+ and RP105-/
- mice were intravenously injected with 2 mg of a cocktail of
monoclonal anti-CII antibodies. Three days later, 10 or 50 μg
of LPS (Sigma-Aldrich) was injected intraperitoneally, and the
mice were examined daily for signs of arthritis. In addition, the
serum TNF-α levels after LPS challenge were determined.
One hour after an intraperitoneal injection of LPS, the sera
were collected and the TNF-α levels were measured using
ELISA kits (Biosource International).
Statistical analysis
The analyses of the incidence of arthritis were performed using
the chi-square analysis. The significance of the differences in
the arthritic indexes, anti-CII antibody levels, and cytokine pro-
duction was determined using either the Mann-Whitney U test
or the Wilcoxon matched pairs test.
Results
RP105-deficient mice developed more severe collagen-
induced arthritisTo examine the role of RP105 in the develop-
m e n t  o f  C I A ,  R P 1 0 5 +/+ and RP105-/- littermate mice were
immunized with CII and monitored for signs of arthritis. As
shown in Figure 1a, RP105-/- mice showed an earlier onset of
disease, and a significantly higher incidence was observed
from day 31 to day 42 than in RP105+/+ mice. After that
period, the incidence of arthritis in RP105+/+ mice increased
and no more differences were observed. The final rates of inci-
dence of arthritis were 85.2% and 73.1% in RP105-/- and
RP105+/+ mice, respectively. As shown in Figure 1b and 1c,
the arthritis index increased gradually, thus indicating the
chronic progression of the disease in a similar manner;Arthritis Research & Therapy    Vol 10 No 5    Tada et al.
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however, the arthritis index in RP105-/- mice was significantly
higher than that in RP105+/+ mice. To histologically determine
the grade of arthritis, the ankle joints were excised, and the
degree of cellular infiltration and synovial hyperplasia was
examined. As shown in Figure 1d, the ankle joints of RP105-/-
mice showed more severe synovitis, especially more inflamma-
tory cell infiltration, than those of RP105+/+ mice at an early
stage (day 35). We also compared the histology of arthritis at
a late stage (7 to 8 weeks). Although RP105-/- mice showed a
relatively severe degree of arthritis, the difference was not sta-
tistically significant (data not shown). To assess the humoral
immune response to CII in RP105-deficient mice, the IgG1
and IgG2a anti-CII antibody levels in the sera of mice were
d e t e r m i n e d  o n  d a y s  2 8  a n d  4 2 .  A s  s h o w n  i n  F i g u r e  1 e ,
although the anti-CII antibodies of both IgG subclasses
seemed to be slightly higher in RP105-/- mice, they were not
significantly different. The anti-CII antibody levels increased
from day 28 to day 42 in RP105+/+ and RP105-/- mice. These
results indicate that RP105-/- mice showed an accelerated
onset of CIA and a more severe CIA and suggest that the
RP105 molecule may therefore regulate the development of
CIA.
Interferon-gamma and tumor necrosis factor-alpha 
production by spleen cells was augmented in RP105-
deficient mice
To analyze the antigen-specific responses of the spleen cells,
the production of cytokines in response to CII was examined.
CII-immunized mice were sacrificed on day 28, and the splen-
ocytes were stimulated with dCII or ConA. As shown in Figure
2a and 2b, the spleen cells from RP105-/- mice produced a
markedly larger amount of IFN-γ and TNF-α in response to CII
Figure 1
The development of collagen-induced arthritis in RP105-deficient mice The development of collagen-induced arthritis in RP105-deficient mice. (a-d) RP105+/+ (n = 26, 13 males and 13 females) and RP105-/- (n = 27, 13 
males and 14 females) mice were immunized with type II collagen (CII), and signs of arthritis were monitored as described in Materials and methods. 
The incidence of arthritis in RP105-/- mice was higher than that in RP105+/+ mice between days 31 and 42 (*P < 0.05 and **P < 0.01 for compari-
son with RP105+/+ mice, chi-square test) (a). The disease severity, expressed as the mean arthritis index (and standard error) of the total mice (b) 
and of the arthritic mice (c), is shown (*P < 0.05 and **P < 0.01 for comparison with RP105+/+ mice, Mann-Whitney U test). (d) A histological exam-
ination was performed in RP105+/+ (n = 20, 10 males and 10 females) and RP105-/- (n = 23, 11 males and 12 females) mice at day 35 (*P < 0.05, 
chi-square test). (e) The anti-CII antibodies of IgG1 and IgG2a classes were measured from RP105+/+ (n = 18) and RP105-/- (n = 19) mice on days 
28 and 42. Values are mean ± standard error (*P < 0.001, Wilcoxon matched pairs test). AU, arbitrary units.Available online http://arthritis-research.com/content/10/5/R121
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than did RP105+/+ mice (P < 0.01 and P < 0.05, respectively),
but not in response to ConA. The production of IL-2 and IL-4
was not significantly different between RP105+/+ and RP105-
/- mice (Figure 2c, d). In addition, IL-17 production from spleen
cells in response to CII (50 μg/dL) was similar in RP105+/+
and RP105-/- mice (781.8 ± 167.3 pg/mL and 840.3 ± 236.0
pg/mL, n = 5).
Dendritic cells from RP105-deficient mice induced more 
interferon-gamma production from lymph node cells 
than dendritic cells from wild-type mice
Because RP105 is not expressed on T cells, we speculated
that the augmented cytokine production by spleen cells from
RP105-deficient mice would be driven by antigen-presenting
cells (APCs). To compare the function of DCs, the splenic
DCs were purified from the CII-immunized RP105+/+  or
RP105-/- mice, mixed with adherent cell-depleted LNCs from
CII-immunized RP105+/- mice, and stimulated with dCII. As
shown in Figure 3a, RP105-/- splenic DCs induced higher
amounts of IFN-γ by LNCs than RP105+/+ DCs at the higher
cell numbers. Prepared splenic DCs consisted of greater than
70% cDCs (CD11c+, B220-) and less than 30% pDCs
(PDCA-1+, B220+), and the subpopulation did not differ
between RP105+/+ and RP105-/- mice (cDCs: 76% ± 5% ver-
sus 75% ± 2%). To evaluate DC function, we measured the
cytokine production from DCs in response to LPS. The splenic
DCs from the two types of mice produced similar amounts of
TNF-α, IFN-γ, and IL-6 and IL-10 in response to various con-
centrations of LPS (Figure 4).
Reduced suppressive function of regulatory T cells in 
response to CII but not to anti-CD3 from RP105-deficient 
mice
We investigated the function of Tregs from RP105-deficient
mice because a recent report showed that the expression of
MD1, a molecule that forms a complex with RP105, regulated
the development of Tregs induced by LPS [38]. We first meas-
ured the number of Tregs in the spleen by flow cytometry. The
percentages of CD4+CD25+ T cells among spleen cells and
of CD25+  cells among CD4+  T cells were not different
Figure 2
The cytokine production from spleen cells in response to denatured type II collagen (CII) and ConA in RP105-deficient mice The cytokine production from spleen cells in response to denatured type II collagen (CII) and ConA in RP105-deficient mice. Mice were immunized 
with CII with complete Freund's adjuvant on day 0 and with CII with incomplete Freund's adjuvant on day 21. The spleen cells from day-28 mice 
were harvested and stimulated with CII or ConA (5 μg/mL) for 48 hours. Interferon-gamma (IFN-γ) (a), tumor necrosis factor-alpha (TNF-α) (b), inter-
leukin-4 (IL-4) (c), and interleukin-2 (IL-2) (d) produced in the culture supernatant were measured by cytometric beads assay. The results from two 
experiments (eight mice per experiment) are shown and expressed as the mean ± standard error (*P < 0.05, **P < 0.01, Mann-Whitney U test).Arthritis Research & Therapy    Vol 10 No 5    Tada et al.
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Figure 3
The functional analysis of dendritic cells (DCs) and regulatory T cells (Tregs) from RP105-deficient mice The functional analysis of dendritic cells (DCs) and regulatory T cells (Tregs) from RP105-deficient mice. (a) The splenic DCs from type II collagen 
(CII)-immunized RP105+/+ or RP105-/- mice were mixed with pooled adherent cells removed lymph node cells (LNCs) from RP105+/- mice, as 
described in Materials and methods. The cells were stimulated with denatured CII for 2 days and interferon-gamma (IFN-γ) production was meas-
ured. Values are mean ± standard error. The DCs from RP105-/- mice induced higher IFN-γ production from LNCs than did the DCs from RP105+/+ 
at 50 × 104 cells. The summary of five experiments, using three mice per group, is shown (*P < 0.05, Mann-Whitney U test). (b) The Tregs (1 × 105) 
purified from the spleens of CII-immunized RP105+/+ and RP105-/- mice were mixed with pooled LNCs (1 × 106) from RP105+/- mice, which were 
immunized with CII 14 days before. The cells were stimulated with denatured CII (20 μg/mL) or anti-CD3 antibody (1 μg/mL) for 2 days and IFN-γ 
production was measured. The percentage suppression (100 × [IFN-γ without Tregs – IFN-γ with Tregs]/IFN-γ without Tregs) is shown. Values are 
mean ± standard error of the six experiments, using three mice per group (*P < 0.05, Wilcoxon matched pairs test).
Figure 4
The inflammatory cytokine production from splenic dendritic cells in response to lipopolysaccharide (LPS) in RP105-deficient mice The inflammatory cytokine production from splenic dendritic cells in response to lipopolysaccharide (LPS) in RP105-deficient mice. The dendritic 
cells (4 × 105) purified from the spleens of RP105+/+ and RP105-/- mice were stimulated with LPS at various concentrations for 24 hours. The super-
natants were collected and the concentrations of tumor necrosis factor-alpha (TNF-α) (a), interferon-gamma (IFN-γ) (b), interleukin-6 (IL-6) (c), and 
interleukin-10 (IL-10) (d) were measured. Values are mean ± standard error of five experiments, using three mice per group.Available online http://arthritis-research.com/content/10/5/R121
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between RP105+/+ and RP105-/- mice (1.47% ± 0.13% ver-
sus 1.33% ± 0.18% and 11.6% ± 0.9% versus 11.7% ±
2.0%, respectively, n = 5). Similarly, the population of Foxp3-
positive CD4+ T cells was not different (RP105+/+ 1.47% ±
0.20% and RP105-/- 1.40% ± 0.16%). Next, we examined the
suppressive function of Tregs by measuring the IFN-γ produc-
tion by LNCs with or without the addition of Tregs. Tregs from
the spleens of CII-immunized RP105+/+ or RP105-/- mice were
mixed with LNCs from CII-immunized RP105+/- mice and stim-
ulated with dCII or anti-CD3 antibody. From the preliminary
experiment, we chose the LNC/Treg ratio for which the sup-
pression of IFN-γ production reached plateau level. As shown
in Figure 3b, although Tregs suppressed the IFN-γ production
from LNCs, the Tregs from RP105-/- mice showed less sup-
pression than those from RP105+/+ mice when they were stim-
ulated with dCII. On the other hand, stimulation with anti-CD3
antibody induced comparable levels of suppression by Tregs
from RP105+/+ and RP105-/- mice (Figure 3b). These results
indicate that RP105-/- mice have attenuated antigen-induced
suppressive function of Tregs or had a decreased number of
CII-specific Tregs.
RP105-deficient mice showed marginally augmented 
disease development in anti-CII antibody and 
lipopolysaccharide-induced arthritis
To investigate the development of arthritis induced by LPS in
RP105-deficient mice, we injected a cocktail of monoclonal
anti-CII antibodies intravenously followed by the intraperito-
neal injection of LPS. As shown in Figure 5a and 5b, RP105+/
+ and RP105-/- mice showed similar development of arthritis
after 2 mg of anti-CII antibodies followed by 50 μg of LPS 3
days later. The arthritis index did not differ between RP105+/+
and RP105-/- mice. We then examined the induction of arthritis
with a decreased dose of LPS to test the response to LPS
Figure 5
The development of anti-CII antibody and lipopolysaccharide (LPS)-induced arthritis and tumor necrosis factor-alpha production after LPS challenge  in RP105-deficient mice The development of anti-CII antibody and lipopolysaccharide (LPS)-induced arthritis and tumor necrosis factor-alpha production after LPS challenge 
in RP105-deficient mice. (a-d) RP105+/+ (n = 9) and RP105-/- (n = 9) mice were injected with a cocktail of monoclonal anti-CII antibodies intrave-
nously and with 50 μg (a, b) or 10 μg (c, d) of LPS intraperitoneally 2 days later. The incidence of arthritis of paws (arthritic paws/total paws) (a, c) 
and disease severity, expressed as the mean arthritis index (and standard error) of mice (b, d), is shown. Arthritis index was significantly higher in 
RP105-/- mice with 10 μg of LPS (*P < 0.05 for comparison with RP105+/+ mice, Mann-Whitney U test). (e, f) RP105+/+ and RP105-/- mice were 
challenged intraperitoneally with 50 μg (e) (n = 10 and 11, respectively) or 10 μg (f) (n = 7 and 9, respectively) of LPS. The serum was collected 1 
hour later and the tumor necrosis factor-alpha levels were measured. Values are mean ± standard error. **P < 0.01, Mann-Whitney U test. CII, type 
II collagen.Arthritis Research & Therapy    Vol 10 No 5    Tada et al.
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more concisely. Whereas the reduction of the dose of LPS to
10 μg decreased the severity of arthritis in RP105+/+ mice,
RP105-/-  mice still developed arthritis with a comparable
severity as induced by 50 μg of LPS (Figure 5c, d). We
compared the production of TNF-α after the intraperitoneal
administration of LPS in RP105+/+  and RP105-/-  mice.
Although the two types of mice produced similar levels of TNF-
α in response to 50 μg of LPS (Figure 5e), RP105-/- mice pro-
duced a significantly higher amount of TNF-α in response to
10 μg of LPS (Figure 5f). These data indicate that RP105-/-
mice showed an enhanced production of TNF-α and arthritis
development with a lower dose of LPS, suggesting a regula-
tory role of RP105 in the in vivo response to LPS.
RP105-deficient mice developed more severe arthritis 
induced by incomplete Freund's adjuvant and CII
We addressed the question of whether the enhanced arthritis
development in RP105-/-  mice was due to the enhanced
response of TLRs to the Mycobacterium-containing adjuvant,
CFA, because it has been shown that the in vivo and in vitro
response to Mycobacterium tuberculosis is regulated by
TLR2, TLR 4, and MyD88 [39-42]. To investigate the impact
of the Mycobacterium-TLR interaction in the augmented arthri-
tis development in RP105-deficient mice, we injected CII
emulsified with IFA twice into RP105+/+ and RP105-/- mice. As
shown in Figure 6, RP105-/- mice still showed a higher inci-
dence of arthritis and more severe disease development,
although they were not as prominent as those observed in CIA
with the regular CFA-based induction. These data indicate that
the augmented arthritis development in RP105-/- mice is not
dependent solely on the CFA and suggest that other TLR lig-
ands, presumably endogenous, might also play a role in this
phenomenon.
Discussion
In the present study, we showed augmented arthritis develop-
ment in RP105-/- mice, with an increased production of IFN-γ
and TNF-α from spleen cells in response to CII. These results
indicate that cell-mediated immune responses to immunized
collagen are enhanced in RP105-deficient mice, thus suggest-
ing RP105 to be a negative regulator of the immune system in
this model.
RP105 was originally found as a molecule that induces B-cell
activation after its ligation, but it has been shown to be
expressed also on macrophages and DCs. The role of RP105
on these cells, however, has not yet been clearly determined.
Recently, Divanovic and colleagues [34] showed that the
Figure 6
The development of collagen-induced arthritis induced with type II collagen (CII) and incomplete Freund's adjuvant (IFA) in RP105-deficient mice The development of collagen-induced arthritis induced with type II collagen (CII) and incomplete Freund's adjuvant (IFA) in RP105-deficient mice. 
RP105+/+ (n = 18, 11 males and 7 females) and RP105-/- (n = 22, 11 males and 11 females) mice were immunized with CII and IFA on days 0 and 
21, and signs of arthritis were monitored. The arthritis incidence was shown as per body (a) and per paw (100 × [number of the arthritic paws/
number of total paws]) (b). The incidence of arthritis in RP105-/- mice was higher than that in RP105+/+ mice on days 42, 66, and 73 (a) as was the 
per-paw incidence after day 38 (b). (*P < 0.05, **P < 0.01, and ***P < 0.001 for comparison with RP105+/+ mice, chi-square test) (c, d) The dis-
ease severity, expressed as the mean arthritis index (and standard error) of total mice (c) and of arthritic mice (d), is shown (*P < 0.05 and **P < 
0.01 for comparison with RP105+/+ mice, Mann-Whitney U test).Available online http://arthritis-research.com/content/10/5/R121
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expression of RP105 by gene transfection suppressed TLR4
signaling in HEK293 cells and that DCs and the macrophages
from RP105-/- mice produced a higher amount of cytokines in
response to LPS. These data indicate that RP105 is an atten-
uator of TLR4-induced signaling [34]. We demonstrated here
that DCs from RP105-deficient mice induced a larger amount
of IFN-γ production from LNCs (Figure 3a), thus indicating the
augmented T-cell-activating function of DCs lacking RP105.
On the other hand, we did not see any significant differences
between DCs from RP105-deficient mice and those from con-
trol mice in cytokine production in response to LPS (Figure 4).
These data are in contrast to those of Divanovic and col-
leagues [34]. The difference might be due to the purity of the
LPS because the conventional LPS that we used might have
been contaminated with a lipopeptide, the TLR2 ligand [34].
Alternatively, the different DC preparation, splenic DCs versus
bone marrow-derived DCs, may have produced different
results.
In the anti-CII antibody and LPS-induced arthritis model, arthri-
tis development and TNF-α production were enhanced in
RP105-deficient mice when a reduced dose of LPS was
administered. Although the difference in the arthritis index
between wild-type and RP105-deficient mice was small in
comparison with that when they were actively immunized,
these results nevertheless support a regulatory role of RP105
in the development of arthritis induced by TLR ligands. On the
other hand, these in vivo results cannot be explained by the in
vitro data of splenic DCs (Figure 4). We therefore need to con-
duct more experiments using specific ligands and cells other
than DCs, such as macrophages or synovial cells, to solve
these problems.
TLRs have been shown to play a role in the acquired immune
responses by promoting cytokine and chemokine production
and costimulatory molecule expression. In addition, a recent
report showed that MD1, a molecule that forms a complex with
RP105, regulated the development of Tregs induced by LPS
[38]. We also observed the impaired Treg function in RP105-
deficient mice. The Tregs play key roles in the maintenance of
immunologic self-tolerance and negative control of a variety of
physiological and pathological immune responses [43,44].
The administration of a Treg-depleting anti-CD25 antibody
induced an accelerated onset of arthritis and a more severe
arthritis in murine CIA [45,46]. In our experiment, the suppres-
sive function of RP105-/- Tregs was impaired when the cells
were stimulated with collagen, but not with anti-CD3 antibody.
These data suggest that reduced Treg function is not intrinsic
but instead is due to insufficient activation when triggered by
antigen presented by APCs. Alternatively, the number of CII-
specific Tregs is decreased in RP105-deficient mice. It has
been shown that the suppressive effect of Tregs is blocked by
DCs activated by TLR ligands, such as LPS or CpG, via IL-6
production [47]. Therefore, it is possible that impaired antigen-
specific Treg induction in RP105-deficient mice is due to an
overproduction of inflammatory cytokines by APCs activated
by immunization with CII and CFA.
Next, we tried to elucidate whether the regulatory role of
RP105 in the development of arthritis is exerted only when the
disease was induced by active immunization using CFA. If
enhanced arthritis development in RP105-deficient mice is
CFA-dependent, it can be speculated that the activation signal
through TLRs evoked by CFA, which contains heat-killed
mycobacteria, is augmented in APCs lacking RP105. How-
ever, RP105-deficient mice showed a higher incidence even
when arthritis was induced using IFA only, thus indicating that
the enhancing effect in arthritis development does not depend
solely on CFA. To explain these results, we hypothesized that
the signals provided by endogenous TLR ligands other than
CFA also made the difference between RP105-deficient and
wild-type mice. Recently, various endogenous ligands of TLR4
and TLR2 have been reported. These molecules include fibrin-
ogen degradation products [15], hyaluronan fragments
[13,14], fibronectin fragments [48], heparan sulfate [49], high-
mobility group box-1 protein [50], and heat shock proteins
[10-12]. These molecules have been shown to induce the acti-
vation or the release of proinflammatory cytokines from DCs or
macrophages. In addition, heat shock proteins, fibrinogen, and
degraded hyaluronan are commonly found in inflamed joints.
Therefore, it is possible that DCs and synovial macrophages
lacking RP105 might be highly activated by these endogenous
ligands, thus resulting in the enhanced development of arthri-
tis. However, this hypothesis has yet to be investigated.
This study has a limitation regarding the specificity of TLRs.
Because we used conventional LPS, which might have been
contaminated with TLR2 ligands, we could not determine the
precise role of TLR4 in our studies. As such, it remains to be
investigated which TLR is regulated by RP105 in these mod-
els using more specific ligands and whether the in vitro activa-
tion and cytokine production from various cells (for example,
macrophages and synovial cells) are altered in the absence of
RP105.
RP105 is also expressed in B cells. B cells from RP105-defi-
cient mice are hyporesponsive to LPS, in contrast to DCs, and
to lipoproteins [30,31]. Our observation that RP105-deficient
mice developed severe arthritis in response to anti-CII anti-
body and LPS and produced more TNF-α in response to LPS
indicated that the hyporesponsiveness of RP105-/- B cells
might be overcome by other cells in vivo. In addition, RP105-
deficient mice were not impaired with respect to T-cell-
dependent antibody production [30]. In keeping with this, we
observed that RP105-/- mice showed comparable levels of
anti-CII antibody in CIA.
Several studies have demonstrated the involvement of TLRs in
arthritis models. The intra-articular triggering of TLRs led to the
joint inflammation [23,24], and TLR2 and TLR4 have beenArthritis Research & Therapy    Vol 10 No 5    Tada et al.
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shown to play a critical role in bacterial cell wall-induced arthri-
tis [18,20]. In human RA, TLRs, including TLR2 and TLR4, are
expressed in synovial cells and are upregulated by proinflam-
matory cytokines [5-9]. RA synovial cells have been shown to
produce various chemokines after the stimulation with TLR2
ligands [51] and inflammatory cytokines after triggering TLR2
or TLR4 [52]. In addition, the suppression of MyD88 or Mal/
TIRAP by transfecting the dominant negative form downregu-
lated the production of cytokines and matrix metalloprotein-
ases from synovial cells [52]. Although these studies
emphasize the proinflammatory roles of TLRs and adaptor mol-
ecules, the regulatory or anti-inflammatory role of TLR family
members is not known. Our data suggest that a potential reg-
ulatory mechanism exists in the TLR-TLR ligand system in
inflammation.
Conclusions
Our study demonstrated that RP105 regulated the cell-medi-
ated immune response by the suppression of APC function
and regulatory T-cell development and, as a result, attenuated
the development of CIA. Further study is necessary to address
the precise interaction between RP105 and various TLRs and
the mechanism of regulation in the inflammatory process in the
development of arthritis.
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